Shares of Motif Bio PLC (LON:MTFB) reached a new 52-week low on Monday . The company traded as low as GBX 28 ($0.37) and last traded at GBX 28 ($0.37), with a volume of 346436 shares trading hands. The stock had previously closed at GBX 30 ($0.39).
A number of research firms have commented on MTFB. Peel Hunt restated a “buy” rating on shares of Motif Bio in a research report on Tuesday, August 14th. Northland Securities restated a “buy” rating on shares of Motif Bio in a research report on Tuesday, August 14th.
Motif Bio Company Profile (LON:MTFB)
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
See Also: How mutual funds make money
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.